Biocryst Pharmaceuticals reported $3.61M in Cost of Sales for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Alnylam Pharmaceuticals ALNY:US USD 41.12M 308K
Biocryst Pharmaceuticals BCRX:US USD 3.61M 3.37M
Chugai Pharma 4519:JP JPY 69.1B 10.73B
Daiichi Sankyo 4568:JP JPY 84.77B 9.97B
Gilead Sciences GILD:US USD 1.4B 47M
GlaxoSmithKline GSK:LN GBP 2.39B 250M
Glaxosmithkline GSK:US GBP 2.39B 250M
Intra Cellular Therapies ITCI:US USD 5.85M 1.2M
IONIS PHARMACEUT IONS:US USD 1.52M 3.23M
Karyopharm Therapeutics KPTI:US USD 980K 41K
Neurocrine Biosciences NBIX:US USD 6.1M 1.3M
Novavax NVAX:US USD 434.59M 163.52M
Ptc Therapeutics PTCT:US USD 14.01M 4.37M
Regeneron Pharmaceuticals REGN:US USD 317.8M 20.7M
Roche Holding ROG:VX 9.56B 717M
Sarepta Therapeutics SRPT:US USD 39.95M 2.16M
Ultragenyx Pharmaceutical RARE:US USD 8.63M 361K
Vertex Pharmaceuticals VRTX:US USD 289.4M 27.6M
YTE INCY:US USD 49.28M 4.05M